Recital 11, Regulation (EU) 2025/117

In forcesince 24 Jan 2025

To ensure the effective involvement of patients, clinical experts and other relevant experts (‘individual experts’) in joint scientific consultation on medical devices and in vitro diagnostic medical devices, the HTA secretariat should start their identification as early as possible. Therefore, at the same time as the JSC Subgroup selects medical devices and in vitro diagnostic medical devices that are to be subject to joint scientific consultation, the JSC Subgroup should also specify, for each joint scientific consultation, the medical condition, the therapeutic area concerned and other specific expertise, based on which the HTA secretariat is to identify individual experts to be consulted during that joint scientific consultation. To identify the individual experts, the HTA secretariat should consult the stakeholder network established pursuant to Article 29 of Regulation (EU) 2021/2282, the European reference networks for rare and complex diseases and other relevant sources, agencies and organisations. In making the final selection, the JSC Subgroup should give priority to individual experts who have expertise, across several Member States, in the medical condition, therapeutic area or the type of health technology that is the subject of the joint scientific consultation.